Navigation Links
Study looks at using the immune system to reduce prostate cancer risk
Date:9/23/2009

ANN ARBOR, Mich. Immune therapies have been explored as a way to treat cancer after it develops. But a new study from the University of Michigan Comprehensive Cancer Center suggests that genetic risk of prostate cancer can be reduced by rescuing critical immune system cells.

The study was done in mice and would need further validation and extensive testing in the lab before being available for humans. But the results are promising for people with a strong family history of cancer or known cancer genes.

Typically, vaccines are based on specific antigens and trigger immunity for a specific pathogen. This is more challenging for cancer as the best lymphocytes that generate immunity to cancer are eliminated during development. In this new study, researchers sought to rescue these key lymphocytes called high affinity cancer-reactive T cells during their development.

The study appears online this week in the Proceedings of the National Academy of Sciences.

The researchers first showed that T cells involved in prostate cancer are deleted because of a gene called lymphotoxin alpha. When the mice lacked lymphotoxin, these T cells came back. These mice become more resistant to prostate cancer. This result suggests that lymphotoxin can be a good target for immune prevention.

Next, the researchers injected a protein targeting lymphotoxin into cancer-susceptible mice. Without treatment, all of these mice will develop prostate cancer, and typically by age 6 months half of them will have metastatic cancer that has spread to distant organs. Although the treated mice still developed tumors, none developed metastases after 30 weeks.

"It appears that the rescued T cells delay tumor formation. It may not be that this approach can prevent cancer altogether, but it can delay the process and slow the aggressive growth and spread of cancer," says study author Pan Zheng, M.D., Ph.D., associate professor of surgery and
'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study
2. Study Suggests a Wider Use for Statins
3. Tired, Stressed Docs Make More Mistakes, Study Finds
4. New Families and Work Institute Study Reveals Declines in the Health of American Workforce
5. 45,000 excess deaths annually linked to lack of health insurance: Harvard study
6. Study of adjuvant endocrine treatment for breast cancer reveals cost of noncompliance
7. Short-term stress enhances anti-tumor activity in mice, Stanford study shows
8. K-State biologist to further study of cellular process that plays role in chronic disease
9. Alzheimers Soars, Global Focus Needed: Study
10. Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer
11. Despite ongoing safety concerns, study finds adverse reactions from contrast agents rarely occur
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 Eye & Vision ... at their office location by expanding a new specialized ... kind comprehensive visual electro-physiology clinic. , By acquiring specialized ... of experience in vision problems, patients with vision loss ... take advantage of the implementation of this specialized vision ...
(Date:7/25/2014)... 2014 The European liquid chromatography reagents ... with analysis and forecast of revenue. The liquid chromatography ... million in 2013, and is estimated to grow to ... 9.4 %, from 2013 to 2018. , Browse through ... to get an idea of the in-depth analysis provided. ...
(Date:7/25/2014)... genes may play a greater role in language delay ... Researchers found more evidence that language traits, such ... inherited. The study involving 473 sets of twins ... language performance for twins than single-born children) was greater ... disputes hypotheses that attribute delays in early language acquisition ...
(Date:7/25/2014)... are switched on or off plays a key role ... UT Southwestern Medical Center researchers have found., The research ... and diabetes, since the transcription factor involved spliced ... the body,s sensitivity to insulin and leptin signaling. Insulin ... of food intake and sugar disposal, and obesity and ...
(Date:7/25/2014)... The American Brain Tumor Association (ABTA) announced today ... Distinguished Events, and Corporate and Special Events Manager - ... be joining the ABTA in the newly created position ... roll out of a nationwide brain tumor volunteer effort ... volunteer network will provide the Chicago-based ABTA with a ...
Breaking Medicine News(10 mins):Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Genes May Be Key to Language Delay in Kids 2Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2Health News:American Brain Tumor Association Recruits Director to Lead New Volunteer Network 2
... and efficacy of first FDA-approved nebulized ... COPD -, NAPA, Calif., May 16 Dey, ... given at the International,Conference of the American Thoracic Society ... Center. One of the presentations details the,effects on dyspnea ...
... mastectomy (total breast removal) for early-stage breast cancer has ... in Rochester. The increase follows a steady decline during ... for this increase are unclear. But they have determined ... resonance imaging (MRI) prior to surgery to treat early-stage ...
... sooner if therapy is working , , FRIDAY, May 16 ... levels of circulating tumor cells can help doctors more ... with metastatic breast cancer, according to a Georgetown University ... weeks, and sometimes months, to determine if a particular ...
... /Xinhua-PRNewswire-FirstCall/ --,Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ... distributor,of high-quality, pharmaceutical grade glucose products in China, ... March 31, 2008., Third Quarter of ... to $20.7 million -- Gross profit rose ...
... May 16 IDM Pharma, Inc.,(Nasdaq: IDMI ... Company,s lead product candidates will be made at ... annual meeting. Data presented,at the meeting will support ... L-MTP-PE, as well as patients with non-small lung,cancer ...
... wake of divorce, illness, violence and other problems that ... experience temporary separations from one or both parents before ... May/June issue of Ambulatory Pediatrics, a new, community-wide study ... at increased risk for learning difficulties and that these ...
Cached Medicine News:Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 2Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 3Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 4Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 5Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 2Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 3Health News:Blood Test Helps Docs Assess Breast Cancer Treatment 2Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 2Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 3Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 4Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 5Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 6Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 7Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 8Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 9Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 10Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 11Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 12Health News:IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting 2Health News:IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting 3Health News:Separation from mom, dad linked with learning trouble in kids 2Health News:Separation from mom, dad linked with learning trouble in kids 3
(Date:7/24/2014)... MOUNTAIN VIEW, Calif. , July 24, 2014 ... ), a leading provider of medication and supply ... hold a conference call Thursday, July 31, to ... What:  , Omnicell Second Quarter 2014 earnings ... 2014, 1:30 p.m. PTWho:  , Randall Lipps, chairman, ...
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... "the company") announced today that the company,s board of directors ... 31 to June 30. Accordingly, DelMar will file a Transition ... Jeffrey Bacha , president and CEO of DelMar stated, ... in achieving our goal of obtaining a senior exchange listing ...
(Date:7/24/2014)... 24, 2014 LSI Medience Corporation today ... with Kineticos, a Raleigh-Durham, NC ... support LSI Medience in identifying opportunities for Presepsin, ... utility in clinical trials. The Presepsin ... diagnosis of sepsis, prognosis of septic patients, early ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2
... Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that ... 2012 at 8:30 a.m. Eastern Time to provide an update ... Inc., a member of the Roche Group (SIX: RO, ROG; ... (888) 660-6127 International Dial-in Number: (973) 890-8355 Participant Code:  40392582 ...
... SINGAPORE, Dec. 30, 2011 /PRNewswire-Asia/ -- Biosensors International Group, ... SGX: B20), a developer, manufacturer and marketer of innovative ... today announced it will be participating in the 30th ... from 9th to 12th January 2012 in San Francisco, ...
Cached Medicine Technology:Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation 2Biosensors International to Participate in the 30th Annual J.P. Morgan Healthcare Conference 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: